ReviewCurrent neurology and neuroscience reports2015
Invasive meningococcal disease in the 21st century—an update for the clinician.
Review in Current neurology and neuroscience reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03682939 (Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population), which is not on this map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive Study)
Who cites it
43 citing papers in PubMed.
- Trial
- Endogenous endophthalmitis secondary to neisseria meningitidis: a case report.BMC ophthalmology · 2026Article
- Meningococcal carriage in UK university students post-pandemic: evidence for MenACWY vaccine impact and ongoing genogroup B risk.Frontiers in public health · 2026Article
- Article
- A Ten-Year Retrospective Review of Medical Records of Patients Admitted with Meningitis or Encephalitis at Five Hospitals in the United States Highlights the Potential for Under-Ascertainment of Invasive Meningococcal Disease.Pathogens (Basel, Switzerland) · 2025Article
- Inactivation of the porB gene reduces the virulence of Neisseria meningitidis in transgenic mice.BMC microbiology · 2025Article
- Article
- Review
- Investigation of invasiveFrontiers in public health · 2025Article
- Tackling immunosuppression by Neisseria gonorrhoeae to facilitate vaccine design.PLoS pathogens · 2024Article
- Meningococcal Pneumonia in a Patient With Pulmonary Amyloidosis and a Recent COVID-19 Infection.Cureus · 2024Article
- Impact of Meningococcal ACWY Vaccination Program during 2017-18 Epidemic, Western Australia, Australia.Emerging infectious diseases · 2024Article
- Immunogenicity of the Conjugate Meningococcal ACWY-TT Vaccine in Children and Adolescents Living with HIV.Microorganisms · 2023Article
- Meningococcal Disease in the Post-COVID-19 Era: A Time to Prepare.Infectious diseases and therapy · 2023Article
- Outcomes of adults with invasive meningococcal disease with reduced penicillin susceptibility in Auckland 2004-2017.Infection · 2023Article
- Epidemiology of invasive meningococcal disease worldwide from 2010-2019: a literature review.Epidemiology and infection · 2023Review
- Product review on the IMD serogroup B vaccine Bexsero®.Human vaccines & immunotherapeutics · 2022Article
- Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19.Human vaccines & immunotherapeutics · 2022Article
- Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature.BMC public health · 2022Review
- Meningococcal vaccines in China.Human vaccines & immunotherapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neisseria meningitidis is a gram-negative diplococcus, for which humans are the only reservoir. While colonization is common, invasive meningococcal disease in the form of meningitis or bacteremia can be devastating and potentially fatal. Certain populations are at higher risk for disease including infants, adolescents, those with asplenia or complement deficiencies, and potentially those with human immunodeficiency virus (HIV) infection. Use of conjugate meningococcal vaccines has impacted disease epidemiology in both high- and low-income countries. Outbreaks of serogroup B disease at university campuses have drawn further attention to the recent development of a novel serogroup B vaccine now approved in many countries. This review covers key aspects of the pathogenesis and management of meningococcal disease, as well as the very recent developments in disease epidemiology, outbreaks, and the evolution of meningococcal immunizations.
Indexed as
Identifiers
25637287What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.